{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:10:33Z","timestamp":1790442633888,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Multidrug-resistant Plasmodium falciparum undermines the efficacy of currently deployed antimalarial therapies in southern Viet Nam.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Between May 2017 and December 2018, this prospective, open-label, single-arm, observational clinical trial, conducted in Binh Phuoc, Dak Nong, Gia Lai, Khanh Hoa, and Ninh Thuan provinces, evaluated the safety and efficacy of oral pyronaridine-artesunate once daily for 3 consecutive days in adults and children with microscopically confirmed P. falciparum malaria. Patients were treated as inpatients for Days 0\u20133, with follow-up visits on Days 7, 14, 21, 28, 35, and 42. The primary outcome was the proportion of polymerase chain reaction (PCR)-adjusted adequate clinical and parasitological response (ACPR) at Day 42.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The cumulative incidence of PCR-adjusted ACPR at Day 42 was 96.1% (95% confidence interval [CI] 91.4\u201398.2; Kaplan\u2013Meier). In the per-protocol analysis, the proportion of patients with Day 42 PCR-adjusted ACPR was 96.1% (147\/153; 95% CI 91.7\u201398.5). The proportion of patients with parasitemia at Day 3 was 24.0% (40\/167; 95% CI 17.7\u201331.2). The prevalences of the Kelch13 (C580Y) mutation were: in Binh Phuoc, 97.7% (43\/44); in Dak Nong, 96.2% (25\/26); in Gia Lai, 57.8% (37\/64); in Khanh Hoa, 66.6% (6\/9); and in Ninh Thuan, 3.6% (1\/28). The majority of artemisinin-resistant isolates also had increased plasmepsin2 copy number (75.9%; 85\/112). There was 1 isolate (Binh Phuoc) that had Kelch13 (C580Y) plus increased plasmepsin2 and Pfmdr1 copy numbers. Asymptomatic transient increases in alanine transaminase and aspartate transaminase were observed at Day 7, resolving by Day 28.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Pyronaridine-artesunate can be used to diversify antimalarial therapy in areas of artemisinin-resistant P. falciparum in Viet Nam.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>ACTRN12618001274268.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz580","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T19:13:08Z","timestamp":1561576388000},"page":"2187-2195","source":"Crossref","is-referenced-by-count":31,"title":["Pyronaridine-artesunate Efficacy and Safety in Uncomplicated Plasmodium falciparum Malaria in Areas of Artemisinin-resistant Falciparum in Viet Nam (2017\u20132018)"],"prefix":"10.1093","volume":"70","author":[{"given":"Phuc","family":"Quang Bui","sequence":"first","affiliation":[{"name":"National Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quang","family":"Hong Huynh","sequence":"first","affiliation":[{"name":"Institute of Malariology, Parasitology & Entomology, Quy Nhon, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duong","family":"Thanh Tran","sequence":"first","affiliation":[{"name":"National Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Thanh Le","sequence":"first","affiliation":[{"name":"Institute of Malariology, Parasitology & Entomology in Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thieu","family":"Quang Nguyen","sequence":"first","affiliation":[{"name":"National Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanh","family":"Van Truong","sequence":"first","affiliation":[{"name":"National Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimol","family":"Khim","sequence":"first","affiliation":[{"name":"Malaria Molecular Epidemiology Unit, Pasteur Institute in Cambodia, Phnom Penh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Witkowski","sequence":"first","affiliation":[{"name":"Malaria Molecular Epidemiology Unit, Pasteur Institute in Cambodia, Phnom Penh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Cong Tran","sequence":"first","affiliation":[{"name":"World Health Organization, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Dorina","family":"Bustos","sequence":"first","affiliation":[{"name":"World Health Organization, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Ringwald","sequence":"first","affiliation":[{"name":"World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinh","family":"Thi Ta","sequence":"first","affiliation":[{"name":"National Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"key":"2020050606274983600_CIT0001","author":"World Health Organization","year":"2015"},{"key":"2020050606274983600_CIT0002","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1475-2875-9-181","article-title":"Monitoring for Plasmodium falciparum drug resistance to artemisinin and artesunate in Binh Phuoc Province, Vietnam: 1998\u20132009","volume":"9","author":"Thanh","year":"2010","journal-title":"Malar J"},{"key":"2020050606274983600_CIT0003","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3201\/eid2304.161872","article-title":"Treatment failure of dihydroartemisinin\/piperaquine for Plasmodium falciparum malaria, Vietnam","volume":"23","author":"Phuc","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2020050606274983600_CIT0004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12936-017-1680-8","article-title":"Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam","volume":"16","author":"Thanh","year":"2017","journal-title":"Malar J"},{"key":"2020050606274983600_CIT0005","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ng.2624","article-title":"Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia","volume":"45","author":"Miotto","year":"2013","journal-title":"Nat Genet"},{"key":"2020050606274983600_CIT0006","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","article-title":"A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study","volume":"17","author":"Witkowski","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2020050606274983600_CIT0007","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0140-6736(04)16767-6","article-title":"Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number","volume":"364","author":"Price","year":"2004","journal-title":"Lancet"},{"key":"2020050606274983600_CIT0008","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S1473-3099(17)30524-8","article-title":"Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam","volume":"17","author":"Imwong","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2020050606274983600_CIT0009","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1473-3099(17)30048-8","article-title":"The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study","volume":"17","author":"Imwong","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2020050606274983600_CIT0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1475-2875-12-70","article-title":"Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials","volume":"12","author":"Duparc","year":"2013","journal-title":"Malar J"},{"key":"2020050606274983600_CIT0011","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1128\/AAC.00039-16","article-title":"Efficacy and safety of pyronaridine-artesunate for treatment of uncomplicated Plasmodium falciparum malaria in Western Cambodia","volume":"60","author":"Leang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2020050606274983600_CIT0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02242-18","article-title":"Efficacy and safety of pyronaridine-artesunate plus single-dose primaquine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Cambodia","volume":"26","author":"Leang","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020050606274983600_CIT0013","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa1007125","article-title":"Pyronaridine-artesunate versus mefloquine plus artesunate for malaria","volume":"366","author":"Rueangweerayut","year":"2012","journal-title":"N Engl J Med"},{"key":"2020050606274983600_CIT0014","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(10)60322-4","article-title":"Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial","volume":"375","author":"Tshefu","year":"2010","journal-title":"Lancet"},{"key":"2020050606274983600_CIT0015","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S0140-6736(18)30291-5","article-title":"Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial","volume":"391","author":"West African Network for Clinical Trials of Antimalarial D","year":"2018","journal-title":"Lancet"},{"key":"2020050606274983600_CIT0016","author":"World Health Organization","year":"2009"},{"key":"2020050606274983600_CIT0017","author":"World Health Organization","year":"2008"},{"key":"2020050606274983600_CIT0018","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature12876","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"Ariey","year":"2014","journal-title":"Nature"},{"key":"2020050606274983600_CIT0019","author":"World Health Organization","year":"1979"},{"key":"2020050606274983600_CIT0020","first-page":"CD006404","article-title":"Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria","volume":"1","author":"Pryce","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2020050606274983600_CIT0021","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01578-16","article-title":"K13 propeller mutations in Plasmodium falciparum populations in regions of malaria endemicity in Vietnam from 2009 to 2016","volume":"61","author":"Thuy-Nhien","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020050606274983600_CIT0022","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/AAC.01466-13","article-title":"Evidence for pyronaridine as a highly effective partner drug for treatment of artemisinin-resistant malaria in a rodent model","volume":"58","author":"Henrich","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020050606274983600_CIT0023","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/infdis\/jix334","article-title":"Association of a novel mutation in the Plasmodium falciparum chloroquine resistance transporter with decreased piperaquine sensitivity","volume":"216","author":"Agrawal","year":"2017","journal-title":"J Infect Dis"},{"key":"2020050606274983600_CIT0024","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/s41467-018-05652-0","article-title":"Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine","volume":"9","author":"Ross","year":"2018","journal-title":"Nat Commun"},{"key":"2020050606274983600_CIT0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1473-3099(18)30068-9","article-title":"Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study","volume":"18","author":"Amato","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2020050606274983600_CIT0026","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s13071-017-2247-9","article-title":"Detection of the Plasmodium falciparum Kelch-13 gene P553L mutation in sporozoites isolated from mosquito salivary glands in South-Central Vietnam","volume":"10","author":"Maeno","year":"2017","journal-title":"Parasit Vectors"},{"key":"2020050606274983600_CIT0027","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1473-3099(17)30635-7","article-title":"Emergence of Plasmodium falciparum triple mutant in Cambodia","volume":"17","author":"Rossi","year":"2017","journal-title":"Lancet Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz580\/29592181\/ciz580.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/10\/2187\/33174486\/ciz580.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/10\/2187\/33174486\/ciz580.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T14:03:16Z","timestamp":1588773796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/10\/2187\/5525051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,6,28]]},"published-print":{"date-parts":[[2020,5,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz580","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5,15]]},"published":{"date-parts":[[2019,6,28]]}}}